A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antigens, CD
Biomarkers, Tumor
Disease-Free Survival
Endometrial Neoplasms
Endothelial Protein C Receptor
Enzyme-Linked Immunosorbent Assay
Female
Fibroblast Growth Factor 2
Humans
Middle Aged
Neovascularization, Pathologic
Receptors, Cell Surface
Thalidomide
Vascular Endothelial Growth Factor A

authors with profiles

Doris M Benbrook